Biocon's Pertuzumab Receives Historic Marketing Authorization in EU as First Biosimilar Approved Under New Clinical Approach

Introduction



In a pivotal move for cancer treatment in Europe, Biocon Limited, a global biopharmaceutical company based in India, announced that the European Commission granted marketing authorization for Pebrilzo®, its biosimilar of pertuzumab. This marking signifies a breakthrough not only for Biocon but also for the healthcare landscape in Europe, providing a new treatment avenue for patients diagnosed with HER2-positive breast cancer.

Significance of Approval



This approval transforms Pebrilzo® into the first biosimilar to gain authorization under the European Medicines Agency's (EMA) newly established clinical approach aimed at simplifying approval processes. Such advancements are essential for enhancing patient access to effective therapies and reducing healthcare costs, particularly amidst rising demands and challenges in healthcare resources across Europe.

The announcement comes shortly after the U.S. FDA approved Biocon's pertuzumab biosimilar, emphasizing the company's commitment to developing biological therapies that address significant unmet medical needs in oncology. "This achievement reinforces our dedication to providing high-quality and affordable biological therapies for patients grappling with HER2-positive breast cancer," said Shreehas Tambe, CEO of Biocon.

Details on Pertuzumab and Its Indication



Pebrilzo® is formulated as a concentrated solution for injection and acts as a monoclonal antibody. It targets the human epidermal growth factor receptor 2 (HER2), binding with high specificity to impede the proliferation of cancer cells expressing HER2.

The indication for Pebrilzo® includes:
1. Neoadjuvant treatment in combination with trastuzumab and chemotherapy for adult patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer at high risk of recurrence.
2. Adjuvant treatment for HER2-positive breast cancer patients.
3. Treatment of unresectable locally recurrent or metastatic HER2-positive breast cancer in combination with trastuzumab and docetaxel.

Clinical studies have employed rigorous analytical characterization processes, demonstrating that Biocon's biosimilar is highly similar to the reference biologic, with no clinically significant differences in quality, safety, and efficacy observed between the two products.

The Growing Oncology Portfolio of Biocon



Biocon's recent success with Pebrilzo® adds to its expanding oncology portfolio, which already includes several compassionate treatments for various cancer types, particularly solid tumors like breast cancer. Furthermore, Biocon’s efforts extend into supportive therapies aimed at managing chemotherapy-induced conditions such as neutropenia and bone health issues associated with cancer treatments.

The ongoing commitment to research and development has resulted in the creation of a comprehensive pipeline featuring over 20 biosimilars alongside innovative therapies like GLP-1 peptides and other advanced generics, broadening Biocon's therapeutic impact globally.

Epidemiology and Future Perspectives



The need for effective treatment options in oncology is underscored by the persistent trend of breast cancer being the most diagnosed cancer among women in Europe. Estimates for 2024 from the European Cancer Information System project a growing incidence, with about 15-20% of breast cancers exhibiting HER2 overexpression.

As healthcare systems continue to evolve, enhancing access to biologic therapies through affordability and availability will remain a priority. Biocon’s milestone in marketing authorization of Pebrilzo® not only marks a notable regulatory achievement but is a step toward addressing the extensive needs of the European healthcare sector.

About Biocon Limited



Biocon Limited, listed on BSE (532523) and NSE (BIOCON), is committed to global healthcare by developing affordable, life-changing medicines. Based in Bengaluru, India, Biocon addresses pressing health challenges, particularly in chronic diseases through innovative biosimilars and generics. The company operates across more than 120 countries with a solid commitment to quality and sustainability, recognized in the SP Global Sustainability Yearbook for its responsible growth initiatives.

For more information, visit Biocon.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.